A Phase 3, 2-Part, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years with Cystic Fibrosisand the G551D Mutation
|Effective start/end date||10/8/09 → 9/30/13|
- Vertex Pharmaceuticals Incorporated
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.